Continued Treatment for Participants Enrolled in Studies of BXQ-350 — ETERNITI  

Neoplasms Clinical Trial

Official title: An Open-Label, Multi-Center, Rollover Study to Provide Continued Treatment Access for Participants Enrolled in Studies of BXQ-350

Status Enrolling by invitation

Clinical Trial Summary

This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.

Clinical Trial Description

This is an open-label, multi-center, rollover study to allow continued treatment access for participants enrolled in studies of BXQ-350. This study is intended for subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. The additional treatment is optional and voluntary.

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.) ;

Related Conditions & MeSH terms

• Neoplasms

• NCT number: NCT04404569
• Study type: Interventional
• Source: Bexion Pharmaceuticals, Inc.
• Status: Enrolling by invitation
• Phase: Phase 1
• Start date: June 8, 2020
• Completion date: July 2024